Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Goodwill & Intangibles Intangibles Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Precision Biosciences (DTIL) Short-term Investments (2024 - 2025)

Precision Biosciences (DTIL) has disclosed Short-term Investments for 2 consecutive years, with $4.8 million as the latest value for Q4 2025.

Quarterly Short-term Investments rose 1053.03% to $4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.8 million through Dec 2025, up 1053.03% year-over-year, with the annual reading at $4.8 million for FY2025, 1053.03% up from the prior year.
Short-term Investments for Q4 2025 was $4.8 million at Precision Biosciences, up from $413000.0 in the prior quarter.
The five-year high for Short-term Investments was $4.8 million in Q4 2025, with the low at $413000.0 in Q4 2024.